Melina Elpi Marmarelis, MD, MSCE

faculty photo
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Attending Physician , Penn Presbyterian Medical Center
Medical Director of Penn Medicine Mesothelioma and Pleural Program, University of Pennsylvania
PC3I Faculty, Penn Center for Cancer Care Innovation, University of Pennsylvania
Physician Lead -Airways Research Program, University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
10th Floor
Philadelphia, PA 19104
Education:
BA (Bachelors in Biochemistry and Molecular Biology )
Dartmouth College, 2007.
MD (Medicine)
Harvard Medical School , 2013.
MSCE (Clinical Epidemiology )
University of Pennsylvania , 2019.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Lung cancer and mesothelioma.

Description of Research Expertise

Clinical trials in lung cancer in mesothelioma.

Selected Publications

Benjamin A. Bleiberg, Dylan G. Scholes, Lauren Reed-Guy, Devaki Dravid, Lova L. Sun, Aditi P. Singh, Roger B. Cohen, Corey J. Langer, Melina E. Marmarelis, Charu Aggarwal: The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing. The Journal of Liquid Biopsy 12, June 2026.

Benjamin A. Bleiberg, Lauren Reed-Guy, Roger B. Cohen, Charu Aggarwal, Corey J. Langer, Aditi P. Singh, Melina E. Marmarelis: Carboplatin plus Pemetrexed versus Pemetrexed alone in Advanced Thymoma and Thymic Carcinoma: A Retrospective Cohort Study. Frontiers June 2026.

Benjamin T. Cooper, Jeffrey D. Bradley, Sushma Patel, Michael A. Pritchett, Steven J. Feigenberg, Kevin C. Ma, Isaac Laniado, Melina E. Marmarelis, Matthew Scarlotta, Joshua K. Sabari, Yi-Wen Ma, Yina Kuang, Kiran Devisetty, Balaji Laxmanan, David M. DiBardino: Novel Intratumoral Radioenhancer (JNJ -1900) with Chemoradiation and Consolidative Immunotherapy for Stage III Unresectable Non -Small Cell Lung Cancer (NSCLC): Early Outcomes from the Phase II CONVERGE Study. ELCC 2026 Poster March 2026.

Adam Barsouk, Alec Heidlauf, Keshav Goel, Lynn Rushkin, Anna Anran Huang, Omar Elghawy, Connie Yu, Lucy Wang, David Yang, Martin Kurian, Lauren Reed-Guy, Lova Sun, Aditi Singh, Charu Aggarwal, Roger B. Cohen, Corey Langer, Melina E. Marmarelis: Osimertinib Dose-Reduction and Survival in First-Line EGFR-Mutated mNSCLC. Lung Cancer 213: 108936, Mar 2026.

Michael Offin...Melina E. Marmarelis: eVOLVE-02 SS5 Meso TiP Abstract entitled: Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line therapy for unresectable pleural mesothelioma (PM): Substudy 5 of the eVOLVE-02 phase 2 study. ELCC March 2026 March 2026 Notes: Poster Presentation. Trial in Progress.

Pascale Tomasini, MD, MSc, Yongsheng Wang, MD, Yongsheng Li, MD, PhD, Enriqueta Felip, MD, PhD, Lin Wu, MD, Jiuwei Cui, MD, PhD Benjamin Besse, MD, PhD, Alexander I. Spira, MD, PhD, Joel W. Neal, MD, Ph, Koichi Goto, MD, PhD, Christina S. Baik, MD, MPH, Melina E. Marmarelis, MD Eiki Ichihara, MD, PhD, Yiping Zhang, MD, Jong-Seok Lee, MD, PhD, Se-Hoon Lee, MD, PhD, James Chih-Hsin Yang, MD, PhD, Sebastian Michels, MD, Zacharias Anastasiou, MS, Joshua C. Curtin, PhD, Xuesong Lyu, PhD, Janine Mahoney, BSN, RN, Levon Demirdjian, PhD, Craig S. Meyer, MS, PhD, MPH, Youyi Zhang, PhD, Isabelle Leconte, PhD, Patricia Lorenzini, MS, Roland E. Knoblauch, MD, PhD, Leonardo Trani, MD, Mahadi Baig, MD, Joshua M. Bauml, MD, Byoung Chul Cho, MD, PhD: Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2. Journal of Clinical Oncology 44(1): 54-65. Jan 2026.

Melina E. Marmarelis, Meijia Zhou, Sajjad Raza, Qing Huang, Kiran Devisetty, Balaji Laxmanan, Rachael L. DiSantostefano, Iftekhar Kalsekar, Daniel Goomez: Real-world Utilization and Outcomes with Pacific Regimen in Stage III Unresectable Non-small Cell Lung Cancer Patients: Results from a Multicenter US Database. ESMO Annual Meeting 2025 October 2025 Notes: Poster Presentation.

Melina E. Marmarelis, Katherina C. Chua, Aisha Hasan, Jorge Da Silva, Stewart Bates, Assieh Saadatpour, Qing Huang: Real-World Characterization of Response Kinetics in Patients with Metastatic NSCLC Receiving First-Line Immunotherapy. IASLC WCLC 25 September 2025 Notes: Poster Presentation.

Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I. Spira, Byoung Chul Cho, Sun Min Lim, Yuichiro Ohe, Adnan Nagrial, Jiunn Liang Tan, Vanina Wainsztein, Elisa Ramos, Maria del Rosario Garcia Campelo , Hiroaki Akamatsu, Danny Nguyen, Alexis B. Cortot, Alona Zer, Dilek Erdem , Rachel E. Sanborn, Till-Oliver Emde, Anna R. Minchom, Bogdan Zurawski, Maria Lurdes Ferreira, James Chih-Hsin Yang, Melina E. Marmarelis, Julia Schuchard, Jefferson Alves, Debopriya Ghosh, Gregor Balaburski, Remy B. Verheijen, Liliana Ribeiro, Mohamed Gamil, Joshua M. Bauml, Mahadi Baig, Natasha B. Leighl : Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-mutated Non-small Cell Lung Cancer: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study. European Journal of Cancer 227: 115624. Sep 2025.

Lauren Reed-Guy, Melina E. Mamarelis: Immunotherapy for Resectable Non-Small Cell Lung Cancer - Not If, But When. JAMA Network Open 8(6): e2517962. Jun 2025.

back to top
Last updated: 03/31/2026
The Trustees of the University of Pennsylvania